319
Participants
Start Date
August 15, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
May 31, 2027
XMT-1660
XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
RECRUITING
New York University Langone Health, New York
NOT_YET_RECRUITING
ICHAN School of Medicine at Mount Sinai, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
NEXT Oncology Virginia, Fairfax
RECRUITING
Winship Cancer Institute, Emory University, Atlanta
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Florida Cancer Specialists, Sarasota
RECRUITING
Tennessee Oncology, PLLC, Nashville
RECRUITING
Henry Ford Health Hospital, Detroit
RECRUITING
Avera Cancer Institute, Sioux Falls
RECRUITING
Northwestern University, Chicago
RECRUITING
Stephenson Cancer Center Oklahoma University Health, Oklahoma City
RECRUITING
Texas Oncology, P.A., Dallas
RECRUITING
MD Anderson, Houston
RECRUITING
Huntsman Cancer Institute, Salt Lake City
RECRUITING
Mayo Clinic Comprehensive Cancer Center, Phoenix
RECRUITING
Comprehensive Cancer Centers of Nevada, Las Vegas
RECRUITING
UCLA, Santa Monica
RECRUITING
UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
RECRUITING
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
Summit Cancer Centers, Spokane
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Mersana Therapeutics
INDUSTRY